login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
CNS PHARMACEUTICALS INC (CNSP) Stock News
USA
- NASDAQ:CNSP -
US18978H5081
-
Common Stock
9.15
USD
-0.05 (-0.54%)
Last: 10/20/2025, 8:00:01 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
CNSP Latest News, Press Relases and Analysis
All
Press Releases
a month ago - By: Benzinga
- Mentions:
BLRX
PRQR
SXTC
BCAB
...
12 Health Care Stocks Moving In Tuesday's After-Market Session
a month ago - By: Benzinga
- Mentions:
HBIO
TTNP
ADAP
ABEO
...
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
2 months ago - By: ACCESS Newswire
CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
2 months ago - By: ACCESS Newswire
CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update
2 months ago - By: ACCESS Newswire
CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
3 months ago - By: ACCESS Newswire
CNS Pharmaceuticals to Participate in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference
5 months ago - By: ACCESS Newswire
CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update
5 months ago - By: ACCESS Newswire
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287
3 months ago - By: ACCESS Newswire
- Mentions:
AKTX
AMIX
NVNO
GRI
...
JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live
3 months ago - By: ACCESS Newswire
CNS Pharmaceuticals Announces Reverse Stock Split
3 months ago - By: ACCESS Newswire
CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment
7 months ago - By: ACCESS Newswire
CNS Pharmaceuticals Reports Full Year 2024 Financial Results
4 months ago - By: ACCESS Newswire
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287
5 months ago - By: ACCESS Newswire
CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit
5 months ago - By: Stocktwits
- Mentions:
VXF
CNS Pharmaceuticals Stock Declines On Wider Q1 Loss: But Retail Stays Unmoved
8 months ago - By: ACCESS Newswire
CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing
5 months ago - By: ACCESS Newswire
CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
7 months ago - By: ACCESS Newswire
CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme
Please enable JavaScript to continue using this application.